Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Letter from the Editor
Imagine if you had a dollar for every time a patient came to your office with the holy grail to cure their diabetes. While you could probably retire off of all those dollars, you probably noticed that every time they show you the cure, it will start working “soon,” and when they come back nothing has changed.
This week our intern Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy, has found scientific evidence that a holy grail does exist and it works both for diabetes and obesity.
Click here to find out why Nour was excited when she found this article.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES -- Diabetes News and Research
Explore three methods to prevent future acute myocardial infarction with diabetes as an underlying agent.
Decreased vagal tone and changes in sympathetic activity may precede the development of cardiometabolic disease or diabetes.
Infusion of certain hormones could help in reducing patient weight and glucose levels.
Did You Know? Metformin Is Associated with a 70% Reduced Mortality in Those with Diabetes and Covid-19
Accumulating observational data suggest that metformin use in patients with type 2 diabetes might reduce the risk of death from COVID-19.
The latest results were published online on July 31. The researchers found that among more than 600 patients with diabetes and COVID-19, the use of metformin was associated with a nearly 70% reduction in mortality after adjustment for multiple confounders—data from four previous studies that also show a decrease in mortality among metformin users compared to nonusers. Taken together, the four observational studies showed that metformin had a positive effect, with an overall 25% reduction in death (P < .00001), albeit with relatively high heterogeneity. The largest of these, from the United States, included 6,256 patients hospitalized with COVID-19 and involved propensity matching. A significant reduction in mortality with metformin use was seen in women but not men (odds ratio, 0.759).
Because metformin exerts various effects beyond its glucose-lowering action, among which are anti-inflammatory effects, it may be speculated that this biguanide might positively influence the prognosis of patients with type 2 diabetes hospitalized for COVID-19. Given the potential confounders inherently found in observational studies, caution is required before drawing any firm conclusions in the absence of randomized controlled trials.
The increasing observational data suggest that metformin use in patients with type 2 diabetes might reduce the risk of death from COVID-19. Still, the randomized trials needed to prove this are unlikely to be carried out, according to experts.
medRxiv. Published online July 31, 2020. Full text; Diabetes Metab. Published online, August 1, 2020. Full text
“Does Metformin Reduce Risk for Death in COVID-19?” Medscape-Aug. 14, 2020
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Brianna Belton, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences
Stephen Rubano, PharmD. Candidate, USF Taneja College of Pharmacy
Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy
Peter Jay Won, Pharm.D. Candidate, University of South Florida, Taneja College of Pharmacy
Sandra Zaki, PharmD Candidate, Florida A&M University
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com